Stock Groups

J&J says its single dose protects against breakthrough COVID-19 for up to 6 months -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO: Vials labeled “COVID-19 Coronavirus Vaccine” and syringe are seen in front of displayed Johnson & Johnson logo in this illustration taken, February 9, 2021. REUTERS/Dado Ruvic/Illustration

(Reuters) -Johnson & Johnson said on Thursday that a real-world study showed its single shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.

This study sponsored by the vaccine maker was done between Jan. 1, and Sept 7, last year. It was before the Omicron variant became known. The study is still being peer-reviewed.

J&J (NYSE:) said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc (NYSE 🙂 as well BioNTech’s Moderna (NASDAQ:).

No waning of protection was found for ICU admissions for all the three vaccines, J&J said.

The firm claimed that the study was done by collecting data from laboratories and claims covering approximately 168,000,000 people.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]